Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large datasets, recognising the increasing use of such technology. Serving the needs of early career and more experienced scientists, this up-to-date reference provides an essential introduction to the process and background of drug discovery, highlighting how computational researchers can contribute to that pipeline.

Features previously unpublished real-life case studies of computational biology approaches currently being used in different phases of the drug discovery pipeline
Exposes readers to the different concepts of drug discovery through a written and graphical interpretation of the process, with a specific focus on features critical for its success
Provides a summary of open source tools and example datasets currently utilised in drug discovery and development, an essential resource for both new and experienced researchers

Índice

Foreword
Preface: the future of drug discovery and health care Eric Schadt
1. The art and science of the Drug Discovery Pipeline (DDP) William T. Loging
2. Computational approaches to drug target identification Thomas B. Freeman and Pek Lum
3. Understanding human disease knowledge through text mining Raul Rodriguez-Esteban
4. Integrating translational biomarkers into drug development Jonathan Phillips
5. Computational phenotypic assessment of small molecules in drug discovery William T. Loging and Thomas B. Freeman
6. Data visualization and the DDP process Ke Xu
7. Information visualization – important IT considerations Telmo Silva
8. The New Drug Application (NDA) and regulatory approval stages William T. Loging, Marilyn Lewis, Bryn Williams-Jones and Roy Mansfield
9. Clinical trial failures and drug repositioning Mark Crawford and Jeff Handler
Appendix I. Additional knowledge-based analysis approaches Raul Rodriguez-Esteban
Appendix II. Open source tools and public data sources Yirong Wang and William T. Loging
Index.